Background
==========

Mean corpuscular volume (MCV), a routine index of whole blood count, refers to the mean volume of red blood cells, and can be detected easily with low cost \[[@b1-medscimonit-25-3976]--[@b3-medscimonit-25-3976]\]. MCV was first used as a diagnostic biomarker for anemia. Recently, several studies have demonstrated that MCV can predict the mortality and morbidity of some diseases, including coronary artery disease \[[@b4-medscimonit-25-3976]--[@b6-medscimonit-25-3976]\]. Macrocytosis predicts adverse outcomes for cases receiving percutaneous coronary intervention, or those with acute decompensated heart failure \[[@b6-medscimonit-25-3976]\].

Coronary artery disease (CAD) is a prevalent disease, greatly threatening human health worldwide. Percutaneous coronary intervention (PCI) is a common revascularization strategy in the management of CAD due to its safety profile, low complication rates, symptom relief, and survival benefits \[[@b7-medscimonit-25-3976]--[@b9-medscimonit-25-3976]\]. MCV and RDW can influence CAD progression, and could be employed as prognostic biomarkers for CAD patients undergoing PCI \[[@b10-medscimonit-25-3976],[@b11-medscimonit-25-3976]\]. However, the correlation of MCV with adverse outcomes in patients with stable CAD (SCAD) was rarely discussed in previously published articles.

In this study, we estimated the predictive significance of MCV in midterm ischemic events among SCAD patients undergoing elective PCI.

Material and Methods
====================

Study population and data collection
------------------------------------

The present study was carried out in Zhongshan Hospital Fudan University from January 2008 to December 2017, and assessed 16 099 adults undergoing PCI, of which 9269 were SCAD patients. Among them, 1031 patients underwent elective PCI and 698 participants were recruited in the follow-up investigation.

Medical information of the patients, including demographics, concomitant diseases, drug prescriptions, lesion characteristics, and procedures, was retrospectively extracted by an experienced cardiologist. Preoperative whole blood samples were processed to ascertain results on RBC (red blood cell), hemoglobin, hematocrit, MCV, red cell distribution width (RDW), WBC, Neutrophil%, Lymphocyte%, and platelets using an automated blood counter (Sysmex XN-2000 Hematology System; Sysmex Corp., Kobe, Japan). Sysmex CS-5100 automated coagulation analyzers measured fibrinogen and d-dimer levels. Serum TSH, T3, T4, FT3, FT4, total bilirubin (TBIL), ALT (alanine transaminase), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and lipoprotein (a) were determined using a Roche Cobas 8000 automatic biochemical-immune analyzer (Roche Diagnostics, Mannheim, Germany).

Endpoint
--------

Cardiovascular events among the patients were clinically monitored. Cardiovascular events such as cardiac death and in-stent restenosis were considered as endpoints and were retrospectively reviewed in November 2017. Once in-stent restenosis occurred, the patients would receive individualized treatments after comprehensively considering the severity of symptoms, co-morbidities, vascular bed, length of restenotic lesion, and plaque burden. Main treatment strategies included drug eluting stents, stent-grafts, and balloon angioplasty. In addition, the patients also received antiplatelet drugs, beta-blockers, or statins treatments according to the status of their complicated diseases. Follow-up information was recorded at 30 days, 6 months, 1 year, 2 years, and 4 years through telephone calls and follow-ups at a clinic. Survival time referred to the duration between first PCI and first event or final date.

Statistical analysis
--------------------

Continuous variables are expressed as average ± standard deviation (SD) or median (interquartile range), and their differences between groups were analyzed using the *t* test (for 2 groups) or Mann-Whitney U test (for more than 2 groups). Normal data distribution was detected using the Shapiro-Wilk test. Patients were grouped according to their quartile points of MCV values. One-way ANOVA or Kruskal-Wallis H was used for comparisons among subgroups. Differences in categorical variables were estimated using the chi-square test or Fisher exact test. Kaplan-Meier method with log-rank test was used for survival analysis. Cox analysis covered clinically important parameters (age, sex, LVEF, hypertension, diabetes, smoke, number of PCI vessels, number of stents, stent length, medication, laboratory results). Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated using multiple analysis to identify independent biomarkers for 2-year cardiac mortality. All calculations were accomplished using SPSS 22.0 (IBM Corp, Chicago, IL). Tests were 2-tailed, and *P*\<0.05 suggested statistical significance for results.

Results
=======

Baseline characteristics stratified by MCV quartiles
----------------------------------------------------

Patients with malignant tumors (n=85), undergoing reoperation procedures (n=312), or with advanced valve diseases (n=23) were excluded. Unfortunately, 52 patients were further lost in the investigation. Finally, a total of 226 eligible patients were included in our study.

The included patients were grouped according to their quartiles of MCV values. The first quartile was defined as the middle value between the smallest value and the median of the data set (MCV: 87.5fL). The second quartile referred to the median value of MCV (89.7 fL). The third quartile was the middle value between the median and the highest values of MCV (92.4 fL). The patients were divided into 4 groups based on these 3 quartile points of MCV value. In statistical application, the quartiles of a ranked set of data values formed 4 subsets whose boundaries were the 3 quartile points. Thus, individual item might be described as "on the upper quartile". The quartile method is helpful in analyzing the trends of a dataset.

Baseline information stratified by the quartile of MCV is demonstrated in [Table 1](#t1-medscimonit-25-3976){ref-type="table"}. Age showed significant differences among the 4 groups, and patients with higher MCV were older (*P*=0.017). Other clinical characteristics, including underlying disease and medication history, did not exhibit obvious differences among groups. Laboratory data were also compared among groups, and the results are summarized in [Table 2](#t2-medscimonit-25-3976){ref-type="table"}. RBC appeared to be lower in patients with higher MCV levels (*P*\<0.001). RDW in group I was remarkably higher than in other groups (*P*=0.002). Patients with high MCV were more likely to have high TBIL (*P*=0.031). [Table 3](#t3-medscimonit-25-3976){ref-type="table"} shows endovascular treatment procedure and the medication at discharge for patients. The stent lengths ranged from 14 to 110 mm, and the average number of placed stents was 1.7±0.8, 1.7±0.8, 1.8±0.7, and 1.6±0.7 in group 1, 2, 3, and 4, respectively (*P*=0.678). The number of PCI vessels in group 4 was less than in other groups, but without a significant difference (*P*\>0.05). No obvious differences were observed in drugs used, such as antiplatelet drugs, beta-blockers (β1-selective agents), or statins (including atorvastatin, Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin) among groups (*P*\>0.05).

Survival analysis and predictors for outcome
--------------------------------------------

The average duration of follow-up was 34.2 months. During this course, 79 patients presented in-stent restenosis. In Kaplan-Meier analysis, the cumulative restenosis rate at 48 months was 35.0%. The incidence of restenosis showed the highest value in the 1^st^ quartile (48.3%) compared with other groups (log-rank test, *P*=0.027). However, the incidence exhibited no significant differences among the 2^nd^ quartile, 3^rd^ quartile, and 4^th^ quartile groups (29.1% *vs*. 31.6% *vs*. 27.8%, *P*\>0.05) ([Figure 1](#f1-medscimonit-25-3976){ref-type="fig"}).

Cox regression analyses were performed to identify indicators for ischemic events. Univariate analysis demonstrated that LVEF (left ventricular ejection fraction), MCV quartiles, ALT, HDL, number of PCI vessels, and stent length were significantly associated with ischemic events. Summarized hazard ratios (HRs) for LVEF, MCV 1^st^ quartile *vs*. 2^nd^ quartile, ALT, HDL, number of PCI vessels, and stents length were 0.972 (95% CI 0.950--0.996; *P*=0.020), 2.037 (95% CI 1.106--3.753; *P*=0.022), 1.011 (95% CI 1.002--1.020; *P*=0.014), 0.333 (95% CI 0.146--0.757; *P*=0.009), 1.219 (95% CI 1.052--1.413; *P*=0.009), and 1.012 (95% CI 1.002--1.023; *P*=0.019), respectively ([Table 4](#t4-medscimonit-25-3976){ref-type="table"}). The restenosis rate for MCV 1^st^ quartile was approximately 2 times higher than that for MCV 2^nd^, 3^rd^, and 4^th^ quartiles, with a baseline hazard ratio of 2.037. After adjustments for confounding factors, the risk of developing ischemic events was still associated with MCV 1^st^ quartile *vs*. 2^nd^ quartile (HRadj=2.047, 95% CI 1.041--4.026; *P*=0.038), ALT (HRadj=1.013, 95% CI 1.004--1.023; *P*=0.004) and number of PCI vessels (HRadj=1.198 95% CI 1.013--1.415; *P*=0.034), but was not associated with LVEF, HDL, or stent length ([Table 5](#t5-medscimonit-25-3976){ref-type="table"}).

Discussion
==========

We estimated the influences of MCV on the prognosis of CAD patients undergoing PCI surgery. We found that patients with decreased MCV were more likely to undergo in-stent restenosis among the entire population. Moreover, multivariate analysis demonstrated that MCV was significantly correlated with stent thrombosis after adjusting for confounding factors, such as ALT, HDL, number of PCI vessels, and stent length. The patients in the 1^st^ quartile, who had the lowest MCV values, exhibited high risk of restenosis.

The first generation of bare metal stents (BMS) significantly reduced the morbidity of restenosis (to roughly 16--44%) \[[@b12-medscimonit-25-3976]\]. The first generation of DES reduced the incidence of restenosis to about 20% within 5 years. Newer DES has reduced this even further, to about 5--7% in 5 years \[[@b13-medscimonit-25-3976]--[@b15-medscimonit-25-3976]\]. Among our selected patients, the morbidity of restenosis (35%) was similar to that reported in earlier published studies. Kaplan-Meier survival analyses showed MCV could predict the occurrence of restenosis. Patients with lowest MCV values exhibited high risk of restenosis. Furthermore, multivariate regression analyses showed that MCV quartiles independently affect in-stent restenosis. Patients with MCV values lower than 87.5 fL exhibited high risk of in-stent restenosis. Myojo et al. reported that macrocytosis obviously increased mortality, as well as main adverse cardiovascular and cerebrovascular events (MACCE), among patients receiving PCI \[[@b6-medscimonit-25-3976]\]. Our study population consisted of SCAD cases undergoing PCI, which might have influenced our results. Osadnik et al. reported that higher RDW values yielded higher comorbidity rates and mortality rates \[[@b10-medscimonit-25-3976]\]. Furthermore, RDW can be used as an indicator for mortality among SCAD patients. Our analysis showed no obvious difference in RDW between restenosis and patency groups. The divergences might be attributed to different study populations, relatively small sample size, and genetic heterogeneity. Further investigations are required to address this issue.

The normal size of RBCs ranges from 82 to 100 fL. Gamaldo et al. observed significant, linear, age-related increases in MCV among white people, even after controlling additional blood indices \[[@b16-medscimonit-25-3976]\]. The results obtained in our study were in accordance with previously published articles. Age was significantly different among the various MCV quartile groups. Bilirubin is an endogenous inhibitor of atherosclerosis, and total bilirubin level possibly influences the risk of cardiovascular diseases \[[@b17-medscimonit-25-3976],[@b18-medscimonit-25-3976]\]. Patients with higher MCV values may also have higher TBIL levels. According to our results, patients with higher MCV value had lower susceptibility to restenosis, and the correlation between MCV and TBIL agrees with these findings.

Cox regression analysis showed LVEF, MCV quartiles, ALT, HDL, number of PCI vessels, and stent length were risk factors for restenosis. After adjustment, MCV, ALT and number of PCI vessels were still correlated with restenosis among SCAD patients undergoing PCI. It is surprising that ALT was an independent risk factor for restenosis, though the underlying mechanism remains unknown. We hypothesized that long-term medication use could cause different degrees of liver injury among SCAD patients. Therefore, ALT became an important index of prognosis among SCAD cases undergoing PCI. Stefanini et al. regarded the number of PCI vessels was a vital procedure factor in evaluating PCI \[[@b19-medscimonit-25-3976]\], and our results are in line with such a conclusion. Our study revealed that MCV quartile were also an independent risk factor. The patients with MCV values within the 1^st^ quartile had high rate of restenosis. However, those in quartile 2, quartile 3, and quartile 4 subgroups did not show significant differences in restenosis incidence. The rate of microcytosis was only 2.2% (5 patients) in our study population, and most of the patients had normal MCV and RDW values. Among these 5 patients, the prevalence of restenosis was 80%. Although the sample size was too small, we still can capture the trend that lower MCV value predicted high risk of restenosis. Further study will shift the focus on microcytosis patients, aiming to explore the phenomena, because the underlying mechanism is still unknown. Decreased MCV is a biomarker for several diseases, including iron deficiency anemia, thalassemia, and other chronic diseases (e.g., microcytic anemia). Inflammation is a leading cause of microcytosis \[[@b20-medscimonit-25-3976]--[@b23-medscimonit-25-3976]\], and inflammatory reaction appears in each and every step of atherosclerosis from its inception to terminal manifestation \[[@b24-medscimonit-25-3976],[@b25-medscimonit-25-3976]\]. The above reasons might explain the close association of small red blood cell size with high risk of restenosis.

MCV is a routine part of complete blood count (CBC) results and is measured by automated blood cell counters, making its detection is easy and inexpensive, and thus not imposing an excessive medical burden on patients or society.

Conclusions
===========

Risk stratification based on MCV value may be an effective and easy way to prevent and quickly treat restenosis among SCAD patients experiencing PCI, thus reducing the occurrence of MACCE and improving patient survival.

Study limitations
-----------------

There are several limitations in this study. First of all, it was a medium-sized, single-center, retrospective study. Therefore, larger-scale and multi-center surveys are required to confirm the results from this study and to elucidate the precise mechanisms underlying the correlations between lower MCV and restenosis among SCAD patients undergoing PCI. In addition, because they were not available for most patients, our analysis did not include data on alcohol consumption, history of heart failure, or cytological/chemical data (e.g., serum iron level, total or unsaturated iron binding capacity \[TIBC or UIBC\], ferritin, transferrin, reticulocyte count, and erythropoietin) that might affect MCV values.
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![Kaplan-Meier curve for primary vessel patency during follow-up stratified by MCV quartile (n=226). Patients in the 1^st^ quartile had lower survival rate than those of 2^nd^ quartile, 3^rd^ quartile, and 4^th^ quartile (*P*=0.027, log-rank test), but there was no significant difference in survival among patients of the 2^nd^ quartile, 3^rd^ quartile, and 4^th^ quartile (*P*\>0.05).](medscimonit-25-3976-g001){#f1-medscimonit-25-3976}

###### 

Baseline clinical characteristics by quartiles of MCV.

                             Group I     Group II    Group III   Group IV    *P* value
  -------------------------- ----------- ----------- ----------- ----------- -----------
  Age (years)                62±9        61±10       62±11       67±9        **0.017**
  Sex no. (%)                                                                0.734
  Male                       40 (67.8)   37 (67.3)   43 (75.4)   40 (72.7)   
  Female                     19 (32.2)   18 (32.7)   14 (24.6)   15 (27.3)   
  LVEF (%)                   62.0±9.6    63.3±6.6    62.3±8.0    62.0±8.2    0.812
  Hypertension no. (%)       43 (72.9)   28 (50.9)   34 (59.6)   34 (61.8)   0.116
  Diabetes no. (%)           11 (39.0)   12 (29.1)   10 (17.5)   10 (18.2)   0.942
  Smoke no. (%)              22 (37.3)   27 (49.1)   19 (33.3)   20 (36.4)   0.340
  Drug application history                                                   
  Antiplatelet               9 (15.3)    15 (27.3)   10 (17.5)   11 (20.0)   0.412
  Beta blockers              4 (6.8)     7 (12.7)    7 (12.3)    5 (9.1)     0.686
  Statins                    4 (6.8)     8 (14.5)    6 (10.5)    5 (9.1)     0.578

LVEF -- left ventricular ejection fraction; Beta blockers -- referring to the β1-selective agents; Statins -- including atorvastatin, Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.

###### 

Laboratory findings by quartiles of MCV.

                    Group I       Group II      Group III     Group IV      *P* value
  ----------------- ------------- ------------- ------------- ------------- -------------
  RBC (mln/mm^3^)   4.7±0.5       4.5±0.4       4.4±0.5       4.2±0.4       **\<0.001**
  HB (mmol/L)       135.6±19.8    137.2±14.4    137.4±15.9    136.7±14.1    0.931
  HCT (%)           39.9±5.7      40.0±3.9      40.2±4.4      40.3±3.9      0.971
  RDW CV (%)        13.4±1.2      13.0±0.7      12.7±0.6      13.1±1.0      **0.002**
  WBC (tys/mm^3^)   7.1±1.8       7.6±2.4       6.8±1.8       6.9±2.3       0.278
  N (%)             64.8±9.1      60.0±14.9     61.2±11.5     61.3±9.9      0.144
  L (%)             26.0±9.0      27.9±10.6     28.1±9.0      28.4±9.4      0.532
  PLT               217.3±63.3    221.7±45.1    200.8±56.0    199.3±59.3    0.081
  FIB               307.4±95.0    288.4±94.9    292.9±83.7    293.7±68.8    0.683
  D Dimer           0.5±0.7       0.3±0.4       0.4±0.5       0.4±0.5       0.716
  T3                1.5±0.3       1.6±0.3       1.5±0.3       1.5±0.3       0.773
  T4                98.8±23.2     100.2±19.1    94.2±18.4     94.7±19.9     0.563
  FT3               4.2±0.7       4.3±0.7       4.3±0.7       4.3±0.8       0.737
  FT4               18.4±18.1     15.8±2.3      16.1±2.2      15.1±2.6      0.286
  TSH               2.9±4.4       1.88±1.5      2.5±1.7       2.8±2.4       0.241
  TBIL              8.8±3.6       8.5±3.3       10.4±4.8      10.3±4.3      **0.031**
  ALT               26.2±15.1     33.7±22.7     27.9±23.9     26.3±19.1     0.185
  TC                4.2±1.1       4.3±1.3       3.8±1.0       4.2±1.0       0.076
  LDL               2.2±0.9       2.4±1.0       2.0±0.9       2.3±0.8       0.113
  HDL               1.0±0.4       1.0±0.3       1.1±0.3       1.1±0.4       0.293
  Lp(a)             392.6±463.4   315.6±351.0   350.7±372.6   315.0±390.6   0.698

RBC -- red blood cell; HB -- hemoglobin; HCT -- hematocrit; RDW CV -- red blood cell distribution width CV; WBC -- white blood cell; N -- neutrophil; L -- lymphocyte; PLT -- platelet; FIB -- fibrinogen; T3 -- triiodothyronine 3; T4 -- triiodothyronine 4; FT3 -- free triiodothyronine 3; FT4 -- free triiodothyronine 4; TSH -- thyroid stimulating hormone; TBIL -- total bilirubin; ALT -- alanine transaminase; TC -- total cholesterol; LDL -- low-density lipoprotein; HDL -- high density lipoprotein; Lp(a) -- lipoprotein(a).

###### 

Clinical characteristics by quartiles of MCV.

                             Group I     Group II    Group III   Group IV    *P* value
  -------------------------- ----------- ----------- ----------- ----------- -----------
  No. of PCI vessel          2.7±1.4     2.8±1.5     2.6±1.5     2.2±1.2     0.164
  No. of stents              1.7±0.8     1.7±0.8     1.8±0.7     1.6±0.7     0.678
  Stent length               44.6±24.0   46.5±21.9   47.5±22.1   39.9±17.8   0.369
  Discharge medication no.                                                   
  Antiplatelet               59 (100)    55 (100)    57 (100)    55 (100)    --
  Beta blockers              59 (100)    55 (100)    55 (96.5)   55 (100)    0.396
  Statins                    54 (91.5)   50 (90.1)   53 (93.0)   55 (100)    0.319

PCI -- percutaneous coronary intervention; Beta blockers -- referring to the β1-selective agents; Statins -- including atorvastatin, Fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.

###### 

Univariable comparison of factors associated with re-infarction event.

                         HR      95% CI         *P* value
  ---------------------- ------- -------------- -----------
  Age (years)            1.000   0.978--1.022   0.993
  Sex No. (%)            1.470   0.869--2.487   0.151
  LEVF (%)               0.972   0.950--0.996   **0.020**
  Hypertension no. (%)   1.097   0.700--1.719   0.687
  Diabetes no. (%)       0.755   0.468--1.220   0.252
  Smoke no. (%)          0.903   0.576--1.415   0.655
  Antiplatelet           1.391   0.768--2.522   0.276
  Beta blocker           1.558   0.678--3.583   0.296
  Statin                 0.927   0.463--1.855   0.829
  MCV                                           **0.036**
  Quartile 1             Ref.                   
  Quartile 3             1.002   0.501--2.004   0.995
  Quartile 4             1.089   0.555--2.135   0.804
  RBC (mln/mm^3^)        1.213   0.767--1.919   0.410
  HB (mmol/L)            0.997   0.983--1.011   0.636
  HCT (%)                0.998   0.949--1.050   0.946
  RDW CV (%)             1.136   0.909--1.420   0.262
  WBC (tys/mm^3^)        1.024   0.923--1.135   0.658
  N (%)                  1.003   0.983--1.023   0.789
  L (%)                  0.993   0.969--1.017   0.567
  FIB                    1.002   1.000--1.004   0.082
  D Dimer                1.028   0.675--1.566   0.897
  T3                     0.483   0.163--1.176   0.101
  T4                     0.990   0.976--1.005   0.196
  FT3                    0.854   0.621--1.175   0.333
  FT4                    1.012   0.996--1.029   0.136
  TSH                    0.990   0.913--1.074   0.810
  TBIL                   0.978   0.923--1.035   0.442
  ALT                    1.011   1.002--1.020   **0.014**
  TC                     1.081   0.888--1.316   0.436
  LDL                    1.042   0.819--1.325   0.740
  HDL                    0.333   0.146--0.757   **0.009**
  LP(a)                  1.000   0.999--1.000   0.315
  No. of PCI vessel      1.219   1.052--1.413   **0.009**
  No. of stents          1.188   0.867--1.627   0.284
  Stents length          1.012   1.002--1.023   **0.019**

LVEF -- left ventricular ejection fraction; MCV -- mean corpuscular volume; RBC -- red blood cell; HB -- Hemoglobin; HCT -- hematocrit; RDW CV -- red blood cell distribution width CV; WBC -- white blood cell; N -- Neutrophil; L -- lymphocyte; FIB -- fibrinogen; T3 -- triiodothyronine 3; T4 -- triiodothyronine 4; FT3 -- free triiodothyronine 3; FT4 -- free triiodothyronine 4; TSH -- thyroid stimulating hormone; TBIL -- total bilirubin; ALT -- alanine transaminase; TC -- total cholesterol; LDL -- low-density lipoprotein; HDL -- high density lipoprotein; LP(a) -- lipoprotein(a); PCI -- percutaneous coronary intervention.

###### 

Predictors for re-infarction event by multivariate Cox regression.

                      HR      95% CI         *P* value
  ------------------- ------- -------------- -----------
  LVEF (%)            0.976   0.953--1.000   **0.054**
  MCV                                        **0.007**
  Quartile 1          Ref.                   
  Quartile 2          2.047   1.041--4.026   **0.038**
  Quartile 3          0.706   0.321--1.551   0.385
  Quartile 4          0.936   0.445--1.967   0.861
  ALT                 1.013   1.004--1.023   **0.004**
  HDL                                        
  No. of PCI vessel   1.198   1.013--1.415   **0.034**
  Stents length       1.010   0.999--1.022   0.079

LVEF -- left ventricular ejection fraction; MCV -- mean corpuscular volume; ALT -- alanine transaminase; HDL -- high density lipoprotein; PCI -- percutaneous coronary intervention.
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